



Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets

September 28, 2026

MILAN--(BUSINESS WIRE)--Sep. 28, 2026-- [Tandem Diabetes Care, Inc.](https://www.businesswire.com/news/home/20260928831177/en/) (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery system for people living with diabetes, ¹ is now available in 12 countries outside the United States. The company is now taking orders and shipping to eligible customers in Belgium, the Czech Republic, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Spain, Sweden, Switzerland, and the United Kingdom.

This press release features multimedia. View the full release here: <https://www.businesswire.com/news/home/20260928831177/en/>



Tandem Mobi, the world's smallest, durable insulin delivery system, now shipping in multiple international markets.

insulin delivery every 5 minutes to help reduce high and low blood sugar. Tandem Mobi also offers multiple wear options, mobile app control through a compatible, personal iPhone,* and a 200-unit cartridge.

Control-IQ+ technology has been evaluated in studies of people with type 1 diabetes, type 1 diabetes during pregnancy, and type 2 diabetes, including studies published by the *New England Journal of Medicine* and the *Journal of the American Medical Association*, with results showing immediate and sustained glycemic improvements, including more time in range and improved sleep.²⁻⁶

"This expansion of Tandem Mobi access is an exciting next step in our strategy to offer a differentiated portfolio of durable insulin pumps to more people around the world," said Igor Friedmann, senior vice president, international. "We look forward to increasing access to Tandem Mobi in more countries in the coming months."

Attendees of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) can visit Tandem Diabetes Care at Booth B.02 to see a live demo of the Tandem Mobi system. The booth will be open for visitors on Tuesday, 29 September through Thursday, 1 October between 9:30-16:30.

Key Tandem Mobi System Features:

- **Impressively Small** – Less than half the size of the t:slim X2 insulin pump and small enough to fit in the coin pocket of a pair of jeans.
- **Wearability Like Never Before** – Users can wear Tandem Mobi on-body with a lightweight adhesive sleeve[†] (sold separately), clip it to clothing, or slip it into a pocket.
- **Infusion Set Options** – Compatible with all existing Tandem-branded infusion sets, including a 12-centimeter tubing option, and allows users to temporarily disconnect from their pump for convenience.
- **Mobile App Control** – Full mobile control through a user's compatible iPhone.* Android compatibility for Tandem Mobi is expected to launch in select countries in 2027.
- **Sensor Compatibility** – Compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. Additional CGM sensor integrations are in development, including integration with Abbott sensors, expected to begin launching in select countries in 2027.
- **Control-IQ+ Automated Insulin Delivery Technology** – Control-IQ+ technology uses sensor glucose values to predict glucose levels 30 minutes ahead and adjust insulin every 5 minutes. Offers Sleep Activity and Exercise Activity settings, and an AutoBolus feature to help prevent hyperglycemia from a missed meal bolus if glucose values are expected to rise above 10 mmol/L.[‡]
- **Clear 200-unit cartridge** – Allows users to see their remaining insulin level.
- **Flexible Pump Control** – The Tandem Mobi pump has a physical button that allows users to deliver a bolus of insulin without their iPhone.

People living with diabetes interested in the Tandem Mobi system in the above countries can learn more at: www.tandemdiabetes.com/mobi.

About Tandem Diabetes Care

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery

systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.

* The mobile app requires a compatible smartphone model and operating system (sold separately). Visit tandemdiabetes.com/compatibility for a complete list of compatible smartphone models and operating systems.

† Do not wear or place your pump more than 12 inches (30.5 cm) above your infusion site. Doing so may result in over delivery of insulin.

‡ If glucose values are predicted to be above 10.0 mmol/L, Control-IQ+ technology calculates an AutoBolus using the Personal Profile settings and a target of 6.1 mmol/L and delivers 60% of that value.

References

1. As of Sept. 2026. Data on file, Tandem Diabetes Care.
2. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. *N Engl J Med* 2019;381:1707-1717 DOI: 10.1056/NEJMoa1907863
3. Breton MD, Kanapka LG, Beck RW, et al. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes, *N Engl J Med* 2020;383:836-845. DOI: 10.1056/NEJMoa2004736
4. Wadwa RP, Reed ZW, Buckingham BA, et al. Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. *N Engl J Med*. 2023;388:991-1001. DOI: 10.1056/NEJMoa2210834
5. Kudva YC, Raghinaru D, Lum JW, et al. A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. *N Engl J Med* 2025;392:1801-1812. DOI: 10.1056/NEJMoa2415948
6. Donovan LE, Lemieux P, Dunlop AD, et al. Closed-Loop Insulin Delivery in Type 1 Diabetes in Pregnancy: The CIRCUIT Randomized Clinical Trial. *JAMA*. 2025;334(24):2176-2185. doi:10.1001/jama.2025.19578

Important Safety Information

For important safety information, please visit tandemdiabetes.com/safetyinfo.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, our ability to increase access to Tandem Mobi in additional countries in the future. These statements are subject to numerous risks and uncertainties, including the risks associated with our ability to sustain commercial scale of Tandem Mobi pumps and the risk that we may encounter other challenges that may delay the availability of Tandem Mobi pumps, the compatibility with Android, or the integration with additional sensors in additional countries. These and other risks are identified and described in greater detail under the "Risk Factors" heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors.

© 2026 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Tandem logos, Tandem Mobi, Control-IQ+, AutoBolus, and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All other third-party marks are the property of their respective owners.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260928831177/en/>

Media Contact:

858-366-6900

media@tandemdiabetes.com

Investor Contact:

858-366-6900

IR@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.